The Sinclair Cancer Research Institute (SCRI) is driving global efforts to combat cancer through cutting-edge research using innovative facilities, performing clinical trials, identifying gaps in cancer care, and mentoring the next generation of cancer researchers.
The SCRI mission is to tackle the most important cancer problems to improve outcomes and offer hope for patients and survivors in our community and beyond. Its mission researchers, together with clinicians and patient partners, are transforming cancer care options informed by scientific rigor, compassion, and collaboration.
The SCRI engages with a variety of industry and academic partners around the world. Within Canada, more than 80 institutions participate in clinical trials run through the (CCTG), which is headquartered at SCRI. CCTG also collaborates with major trial networks in the United States, Europe, Australia, New Zealand, Japan, and Korea.
Members of the Cancer Care and Epidemiology (CCE) division of SCRI work extensively with Cancer Care Ontario and the Institute for Clinical and Evaluative Sciences. Both CCTG and the Cancer Biology and Genetics (CBG) division of SCRI have significant partnerships with the , including two initiatives led by Queen鈥檚 researchers: the and the .
SCRI and Queen鈥檚 have partnered with the to establish a Kingston site for the Canada-wide . Kingston is one of four sites conducting whole genome sequencing of cancer cohorts.
The SCRI offers opportunities for undergraduate, graduate, and postdoctoral training in partnership with several departments at the university, including Biomedical and Molecular Sciences, Oncology, Pathology and Molecular Medicine, Public Health Sciences, Mathematics and Statistics, and the School of Policy Studies.
SCRI also operates a training program in collaborative cancer research that is tailored to meet the needs of graduate and postdoctoral trainees for future employment in a wide range of clinical and research careers.